What Is SR-17018? Complete Guide to G Protein-Biased Mu Opioid Agonists

The Search for Safer Opioid Receptor Modulation

For decades, researchers have pursued a seemingly impossible goal: harness the powerful analgesic properties of the mu opioid receptor (MOR) system while eliminating the dangerous effects that have fueled a global crisis. Traditional MOR agonists like morphine activate multiple intracellular signaling cascades simultaneously, producing both therapeutic effects and life-threatening complications.

SR-17018 represents a breakthrough in this pursuit. As a G protein-biased mu opioid agonist, this research compound demonstrates remarkable selectivity for the signaling pathways associated with beneficial effects while minimizing activation of pathways linked to adverse outcomes.

This comprehensive guide examines SR-17018 from multiple angles: its molecular mechanism, the science of biased agonism, practical research applications, and essential handling specifications. Whether you are designing new protocols or evaluating compounds for your laboratory, understanding SR-17018's unique pharmacological profile is essential.

TL;DR: SR-17018 at a Glance

What it is: SR-17018 is a highly selective G protein-biased agonist at the mu opioid receptor (MOR), designed to preferentially activate G protein signaling over beta-arrestin2 recruitment.
Key advantage: Preclinical studies demonstrate that G protein-biased MOR agonists like SR-17018 may produce analgesic effects with reduced respiratory depression and slower tolerance development compared to unbiased agonists.
Mechanism: SR-17018 binds to the orthosteric site of the mu opioid receptor and stabilizes receptor conformations that favor Gi/o protein coupling while minimizing beta-arrestin2 (ARRB2) recruitment.
Research value: This compound serves as an essential pharmacological tool for dissecting opioid receptor signaling pathways and testing the biased agonism hypothesis in various experimental models.
Availability: High-purity SR-17018 is available for research purchase in quantities suitable for both in vitro and in vivo studies.

What Is SR-17018?

SR-17018 is a synthetic small molecule that acts as a potent and selective agonist at the mu opioid receptor (MOR, also designated OPRM1). What distinguishes SR-17018 from classical MOR agonists is its biased agonism profile: it preferentially activates G protein-mediated signaling pathways while demonstrating markedly reduced efficacy for beta-arrestin2 (beta-arr2, ARRB2) recruitment.

Chemical Identity and Classification

SR-17018 belongs to a class of compounds developed specifically to test the hypothesis that separating G protein signaling from beta-arrestin recruitment at the mu opioid receptor could yield improved pharmacological profiles. It was designed and characterized by research groups investigating structure-activity relationships among biased opioid ligands.

The compound is classified as:

A mu opioid receptor agonist (MOR agonist, OPRM1 agonist)
A G protein-biased ligand (Gi/o-biased)
A beta-arrestin2-sparing agonist
A functionally selective opioid

Historical Context

The development of SR-17018 emerged from extensive research into the "biased agonism hypothesis" at opioid receptors. This hypothesis proposes that the beneficial analgesic effects of MOR activation are mediated primarily through G protein signaling, while adverse effects such as respiratory depression, constipation, and tolerance development are driven substantially by beta-arrestin-dependent pathways.

Early proof-of-concept studies with other biased ligands, including TRV130 (oliceridine) and PZM21, demonstrated that it was chemically feasible to create MOR agonists with varying degrees of bias. SR-17018 emerged as a tool compound with a particularly clean pharmacological profile for research applications.

How Does SR-17018 Work?

Understanding SR-17018's mechanism requires examining the molecular events that occur when any ligand binds to the mu opioid receptor. The MOR is a G protein-coupled receptor (GPCR) that can activate multiple downstream signaling cascades depending on the specific ligand that binds to it.

The Mu Opioid Receptor: A Two-Pathway System

When a classical full agonist like morphine binds to the MOR, it triggers two major intracellular signaling cascades:

Pathway 1: G Protein Signaling (Gi/o)

The activated receptor couples to inhibitory G proteins (Gi and Go)
This leads to inhibition of adenylyl cyclase and reduced cAMP production
Downstream effects include neuronal hyperpolarization, reduced neurotransmitter release, and analgesia
This pathway is generally associated with the therapeutic, pain-relieving effects of opioids

Pathway 2: beta-Arrestin Recruitment

Following G protein activation, G protein-coupled receptor kinases (GRKs) phosphorylate the receptor
Beta-arrestin proteins (particularly beta-arrestin2/ARRB2) are recruited to the phosphorylated receptor
This initiates receptor internalization and additional signaling cascades
Research has linked this pathway to respiratory depression, constipation, and accelerated tolerance development

SR-17018's Biased Mechanism

SR-17018 binds to the same orthosteric binding pocket on the MOR as morphine and other classical opioids. However, the specific molecular interactions between SR-17018 and the receptor stabilize a unique receptor conformation.

This conformation efficiently couples to Gi/o proteins but adopts a geometry that is suboptimal for GRK-mediated phosphorylation and subsequent beta-arrestin2 recruitment. The result is functional selectivity: SR-17018 activates one signaling arm of the receptor while minimizing activation of the other.

Quantifying Bias: The Bias Factor

Researchers quantify biased agonism using "bias factors" calculated from operational model analyses. These values compare a compound's relative efficacy for G protein signaling versus beta-arrestin recruitment, normalized to a reference agonist (typically DAMGO or morphine).

SR-17018 demonstrates substantial G protein bias, with published bias factors indicating preferential G protein signaling over beta-arrestin2 recruitment. In standard GTPgammaS binding and cAMP accumulation assays, SR-17018 functions as a full agonist. In contrast, beta-arrestin recruitment assays typically show markedly reduced efficacy or apparent antagonism.

Receptor Binding Profile

SR-17018 exhibits high affinity for the mu opioid receptor with selectivity over delta and kappa opioid receptor subtypes. The binding profile ensures that observed effects in research models can be attributed primarily to MOR engagement rather than activity at related receptors.

Why Biased Agonism Matters

The concept of biased agonism has transformed how researchers approach GPCR pharmacology. For the mu opioid receptor specifically, biased agonism offers a potential solution to one of pharmacology's most persistent challenges: separating opioid analgesia from opioid harm.

The Traditional Opioid Problem

Classical MOR agonists like morphine, fentanyl, and oxycodone are powerful analgesics. They are also responsible for:

Respiratory depression causing fatal overdoses
Rapid tolerance development requiring dose escalation
Physical dependence and withdrawal syndromes
Severe constipation and other gastrointestinal effects
Reward and reinforcement driving addictive behaviors

These effects have contributed to a devastating public health crisis. Researchers have long sought to understand whether these adverse effects are inseparable from analgesia or whether they represent distinct biological processes that could be pharmacologically separated.

The Beta-Arrestin Hypothesis

Landmark studies in beta-arrestin2 knockout mice provided crucial evidence. Mice lacking the ARRB2 gene showed enhanced and prolonged analgesic responses to morphine while demonstrating reduced respiratory depression, less constipation, and slower tolerance development.

These findings suggested that beta-arrestin2 signaling might be responsible for many adverse opioid effects. If a drug could activate G protein signaling without recruiting beta-arrestin2, it might produce "cleaner" analgesia.

Observed Effects in SR-17018 Studies

Preclinical research with SR-17018 and related G protein-biased MOR agonists has generated compelling data supporting the biased agonism hypothesis:

Respiratory Effects

Studies comparing SR-17018 to morphine in rodent models have demonstrated that equi-analgesic concentrations of SR-17018 produce significantly less respiratory depression. This effect has been attributed to the reduced beta-arrestin signaling component.

Tolerance Development

Chronic administration studies suggest that tolerance to G protein-biased agonists may develop more slowly than tolerance to unbiased agonists. The mechanism is thought to involve reduced receptor downregulation and desensitization in the absence of robust beta-arrestin recruitment.

Gastrointestinal Transit

Some studies have reported reduced effects on gastrointestinal motility with biased agonists, though this finding has been less consistent across different experimental paradigms.

Scientific Debate and Ongoing Research

It is important to note that the biased agonism hypothesis remains an active area of scientific investigation. Some researchers have challenged the direct linkage between beta-arrestin signaling and adverse opioid effects, suggesting the picture may be more complex.

SR-17018 serves as a valuable tool for testing these competing hypotheses. Its clean pharmacological profile allows researchers to isolate the contributions of G protein versus arrestin signaling in various experimental contexts.

Key Research Applications

SR-17018 has become an essential pharmacological tool across multiple research domains. Its well-characterized bias profile makes it valuable for both basic mechanistic studies and translational research programs.

Receptor Signaling Studies

Researchers use SR-17018 in cell-based assays to:

Characterize the structural determinants of biased agonism at the MOR
Map the intracellular signaling cascades downstream of G protein versus beta-arrestin pathways
Validate assay systems for screening novel biased ligands
Investigate receptor conformational dynamics using biophysical techniques

Pain and Analgesia Research

In preclinical pain models, SR-17018 enables researchers to:

Compare analgesic efficacy between biased and unbiased MOR agonists
Evaluate the relationship between bias factor and therapeutic index
Study tolerance development mechanisms in chronic administration paradigms
Investigate sex differences in opioid pharmacology using biased probes

Respiratory Physiology Studies

The respiratory-sparing properties of G protein-biased agonists make SR-17018 useful for:

Dissecting the neural circuits underlying opioid-induced respiratory depression
Identifying the specific signaling pathways that modulate brainstem respiratory centers
Developing assay systems to evaluate respiratory safety of novel compounds

Addiction and Reward Research

SR-17018 serves as a comparator compound in studies examining:

The role of beta-arrestin signaling in opioid reward and reinforcement
Self-administration behaviors with biased versus unbiased agonists
The molecular basis of opioid dependence and withdrawal

Drug Development Tool Compound

Pharmaceutical researchers employ SR-17018 as:

A reference compound for validating bias quantification methodologies
A benchmark for comparing novel lead compounds
A positive control in high-throughput screening campaigns

SR-17018 Specifications

The following specifications represent typical values for research-grade SR-17018. Researchers should consult the Certificate of Analysis (CoA) for lot-specific data.

Parameter	Specification
Chemical Name	SR-17018
CAS Number	2097938-73-5
Molecular Formula	C22H28N2O3
Molecular Weight	368.47 g/mol
Physical Form	White to off-white powder
Purity	Greater than or equal to 98% (HPLC)
Solubility	Soluble in DMSO; limited aqueous solubility
Storage Temperature	-20 degrees Celsius (desiccated)
Stability	Stable for 2 years when stored properly

Pharmacological Parameters

Assay	Value	Notes
MOR Binding Affinity (Ki)	Approximately 2-5 nM	Radioligand displacement
G Protein EC50 (cAMP)	Approximately 97 nM	Full agonist efficacy
Beta-Arrestin2 Recruitment	Minimal to undetectable	PathHunter or BRET assays
Bias Factor	Greater than 10 (G protein vs arrestin)	Relative to morphine
DOR Selectivity	Greater than 100-fold vs MOR	MOR-selective
KOR Selectivity	Greater than 100-fold vs MOR	MOR-selective

High-purity SR-17018 for research applications is available in our online shop.

Handling and Storage

Proper handling and storage of SR-17018 ensures compound integrity and experimental reproducibility. The following guidelines are recommended for research laboratories.

Storage Conditions

Temperature: Store at -20 degrees Celsius for long-term stability
Environment: Keep in a desiccated environment to prevent moisture absorption
Light protection: Store in amber vials or protect from prolonged light exposure
Container: Use airtight containers with appropriate seals

Solution Preparation

SR-17018 demonstrates limited aqueous solubility. For most applications:

Prepare concentrated stock solutions in DMSO (10-50 mM stocks are typical)
Dilute into aqueous buffers immediately before use
Final DMSO concentration should not exceed 0.1-1% for cell-based assays
For in vivo studies, common vehicles include DMSO/Tween-80/saline formulations

Stability Considerations

DMSO stock solutions may be stored at -20 degrees Celsius for several months
Avoid repeated freeze-thaw cycles; aliquot stocks upon preparation
Aqueous dilutions should be prepared fresh for each experiment
Monitor for precipitation when diluting into aqueous media

Safety Handling

Handle as a pharmacologically active compound
Use appropriate personal protective equipment (gloves, lab coat, eye protection)
Work in well-ventilated areas or fume hoods when handling powder
Dispose of waste according to institutional guidelines for pharmaceutical compounds

Frequently Asked Questions

What is the difference between SR-17018 and morphine?

SR-17018 and morphine are both mu opioid receptor agonists, but they differ fundamentally in their signaling profiles. Morphine is an unbiased or slightly beta-arrestin-biased agonist that activates both G protein and beta-arrestin pathways robustly. SR-17018 is a G protein-biased agonist that preferentially activates G protein signaling while minimizing beta-arrestin2 recruitment. In preclinical models, this translates to analgesic effects with potentially reduced respiratory depression and slower tolerance development for SR-17018 compared to morphine at equi-analgesic concentrations.

What concentrations of SR-17018 are used in research?

Appropriate concentrations depend on the specific application. For in vitro receptor binding and functional assays, concentrations typically range from 0.1 nM to 10 micromolar, with EC50 values for G protein activation around 97 nM. For cellular assays examining signaling, 1-1000 nM concentration ranges are common. For in vivo studies in rodent models, published protocols have utilized doses ranging from 1-30 mg/kg administered via intraperitoneal or subcutaneous routes. Researchers should optimize concentrations for their specific experimental systems.

How do I prepare SR-17018 solutions for experiments?

Due to limited aqueous solubility, SR-17018 should first be dissolved in DMSO to create a concentrated stock solution (commonly 10-50 mM). This stock can be stored at -20 degrees Celsius in aliquots. For working solutions, dilute the DMSO stock into your assay buffer immediately before use, ensuring the final DMSO concentration remains below levels that affect your experimental system (typically less than 0.1-1% for cell-based assays). For in vivo administration, prepare vehicle solutions containing DMSO, solubilizing agents such as Tween-80 or PEG-400, and saline.

What is a bias factor and why does it matter?

A bias factor is a quantitative measure that compares a ligand's relative efficacy for activating one signaling pathway versus another. For opioid receptors, bias factors typically compare G protein activation to beta-arrestin recruitment, normalized to a reference compound like morphine. A bias factor greater than 1 toward G protein indicates preferential G protein signaling. SR-17018 demonstrates bias factors greater than 10 favoring G protein over beta-arrestin2. This metric matters because it predicts the pharmacological profile of the compound and allows researchers to compare biased ligands and correlate bias with functional outcomes in preclinical models.

Is SR-17018 selective for the mu opioid receptor?

Yes, SR-17018 demonstrates high selectivity for the mu opioid receptor (MOR) over other opioid receptor subtypes. Published data indicate greater than 100-fold selectivity over both delta opioid receptors (DOR) and kappa opioid receptors (KOR). This selectivity is important for attributing observed effects specifically to MOR modulation rather than off-target activity at related receptors. Researchers studying MOR-specific signaling can use SR-17018 with confidence that results reflect MOR engagement.

References

Schmid CL, Kennedy NM, Ross NC, et al. Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics. Cell. 2017;171(5):1165-1175.e13. doi:10.1016/j.cell.2017.10.035
Gillis A, Gondin AB, Kliber A, et al. Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. Sci Signal. 2020;13(625):eaaz3140. doi:10.1126/scisignal.aaz3140
Raehal KM, Walker JK, Bohn LM. Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther. 2005;314(3):1195-1201. doi:10.1124/jpet.105.087254
Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science. 1999;286(5449):2495-2498. doi:10.1126/science.286.5449.2495
Kliewer A, Gillis A, Hill R, et al. Morphine-induced respiratory depression is independent of beta-arrestin2 signalling. Br J Pharmacol. 2020;177(13):2923-2931. doi:10.1111/bph.15004
DeWire SM, Yamashita DS, Rominger DH, et al. A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013;344(3):708-717. doi:10.1124/jpet.112.201616
Manglik A, Lin H, Arber DK, et al. Structure-based discovery of opioid analgesics with reduced side effects. Nature. 2016;537(7619):185-190. doi:10.1038/nature19112

For research use only. Not for human consumption.

Ready to advance your opioid receptor research? Browse our SR-17018 products or visit our complete catalog of research compounds.

Conducting your own research?